Abstract: Disclosed are esters and a process for the preparation of the esters represented by formula 1: The process includes reacting an alcohol with a long-chain acid R2COOH or long-chain ester R2COOR4 in the presence of an organic solvent and an enzyme with or without the removal of water.
Type:
Grant
Filed:
August 8, 2007
Date of Patent:
April 19, 2011
Assignee:
Eastman Chemical Company
Inventors:
Stephanie Kay Clendennen, Neil Warren Boaz
Abstract: The present invention provides antibiofilm composition comprising two or more agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K for preventing growth and proliferation of biofilm-embedded microorganisms in wound care, oral care, and disease-related infections and methods of treatment in mammals. The invention further provides methods for preparing medical devices, and wound care devices using an antibiofilm composition comprising two or more antimicrobial agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K.
Abstract: The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.
Abstract: The invention relates to a methods and compositions for treating a surface, suspension or solution contaminated with a PrPSc prion protein or a surrogate thereof. The methods and compositions employ a combination of one or more enzymes effective to cleave a prion protein to fragments having a non-infective molecular weight, and one or more agents selected to favour conformational unfolding of the PrPSc prion protein while not denaturing the one or more enzymes.
Type:
Application
Filed:
December 10, 2010
Publication date:
April 14, 2011
Applicant:
NOVAPHARM RESEARCH (AUSTRALIA) PTY LTD.
Inventors:
Steven Kritzler, Alex Sava, Michael Zalunardo
Abstract: A proteinase therapy has been invented to eliminate solid tumors by destroying tumors' solid structure and killing cancer cells by cleaving vital extracellular matrix proteins C-terminally, N-terminally or both with cell membrane intact and limited adverse effects. The micro-scale intratumoral proteinase K therapy is tumor specific but not cancer type specific. Proteinase K therapy can be operated on multiple tumors on multiple occasions, if necessary. It may be employed to eliminate any solid tumor to prolong a cancer patient's life span.
Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.
Type:
Application
Filed:
July 30, 2010
Publication date:
April 14, 2011
Applicants:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Leopold GRILLBERGER, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
Abstract: Novel enzyme variants including protease variants derived from the DNA sequences of naturally-occurring or recombinant non-human proteases are disclosed. The variant proteases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant protease to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor protease. Such variant proteases have properties which are different from those of the precursor protease, such as altered wash performance. The substituted amino acid residue correspond to positions 27, 45, 170, 181, 251 and 271 of Bacillus amyloliquefaciens subtilisin. Additional variants comprising at least one additional substitution at a position selected from 1, 14, 49, 61, 87, 100, 102, 118, 128, 204 and 258 of Bacillus amyloliquefaciens subtilisin are also described.
Type:
Application
Filed:
May 10, 2010
Publication date:
April 14, 2011
Applicant:
Danisco US Inc.
Inventors:
Ayrookaran J. Poulose, David A. Estell, James T. Kellis, JR., Richard R. Bott
Abstract: The present invention provides methods and compositions comprising at least one neutral metalloprotease enzyme that has improved stability in the presence of a metal chelator. In some embodiments, the neutral metalloprotease finds use in cleaning and other applications comprising citrate. In some particularly preferred embodiments, the present invention provides methods and compositions comprising variant neutral metalloprotease(s) engineered to resist citrate-induced autolysis.
Type:
Application
Filed:
October 23, 2008
Publication date:
April 7, 2011
Inventors:
Ronaldus W. J. Hommes, Amy D. Liu, Andrew Shaw, Louise Wallace
Abstract: The present invention relates to recombinant furin (rFurin) and methods for producing rFurin. More specifically, the invention relates to substantially animal protein-free rFurin and methods for producing substantially animal protein-free rFurin.
Type:
Application
Filed:
December 3, 2010
Publication date:
March 31, 2011
Applicants:
BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
Inventors:
Barbara Plaimauer, Simone Von Fircks, Leopold Grillberger, Meinhard Hasslacher, Roland Geyer, Artur Mitterer, Manfred Reiter
Abstract: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
Type:
Application
Filed:
October 13, 2010
Publication date:
March 31, 2011
Inventors:
Gabriel A. Mintier, Jian Chen, John N. Feder, Bowman Miao, Rex Arnold Parker
Abstract: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.
Abstract: The invention relates to the field of cell biology. In detail it relates to the obtainment of mesenchymal stem cells from human tissue. This invention might be applicable in healing within the frame of the treatment of several diseases. Due to the invention it will be possible to obtain mesenchymal stem cells from human tissue with high homogeneity of the cell suspension, since the used method for obtaining mesenchymal stem cells from human tissue comprises the crushing and enzymatical treatment of the tissue with collagenase solution in Eagle medium in the Dulbecco modification, removal of erythrocytes by the aid of the lysis solution and subsequent filtration of the prepared suspension; as human tissue fat tissue or decidual or amniotic placenta membrane or chorion placenta stroma is used, whereas the filtration is performed sequentially by the use of filters comprising a pore size of 100 ?m and 10 ?m.
Abstract: The present invention relates to an in vitro method of diagnosing a drug-associated angioedema or a predisposition thereto in a subject being suspected to having developed or of having a predisposition to develop a drug-associated angioedema or in a subject being intended to be treated with a drug associated with the development of angioedema, the method comprising determining in a biological sample from said subject the presence or absence of a disease-associated mutation in a nucleic acid molecule regulating the expression of or encoding coagulation factor XII; wherein the presence of such a mutation is indicative of a drug-associated angioedema or a predisposition thereto.
Abstract: A process of producing a protease in a plant or in plant cells, comprising (a) providing a plant comprising a heterologous nucleotide sequence comprising a coding sequence encoding a fusion protein, said fusion protein comprising: an apoplast or plastid signal peptide; a SUMO protein or a derivative of a SUMO protein; and a zymogen of said protease, and (b) expressing said fusion protein.
Abstract: The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal ?-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.
Type:
Application
Filed:
July 21, 2010
Publication date:
March 3, 2011
Applicant:
GLYCOFI, INC.
Inventors:
Robert Collier Davidson, Tillman Ulf Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen Robin Hamilton
Abstract: A method of regulating an activity of metalloproteinase 9 (MMP-9) is disclosed. The method comprises contacting the MMP-9 with an agent which specifically interacts with an OG domain of the MMP-9. Molecules capable of specifically interacting with the OG domain, methods of identifying same, pharmaceutical compositions comprising same and uses thereof are also disclosed.
Abstract: The present invention provides a process to make a gelatine hydrolysate, a gelatine hydrolysate, and gelatine compositions including gelatine hydrolysates. More specifically, the invention provides gelatine compositions having a reduced tendency to cross-link and improved dissolution properties.
Abstract: A use of vivapain-4 (VX-4), which is a cysteine protease of Plasmodium vivax, showing pH-dependent switching of substrate specificity, is provided. More specifically, a method of treating a parasitic disease caused by Plasmodium vivax by inhibiting VX-4; a method of screening a protease inhibitor acting on VX-4, wherein the protease inhibitor is useful as an anti-malarial agent acting on Plasmodium species, for example, Plasmodium vivax; and a method of identifying the activity of VX-4, are provided.
Type:
Application
Filed:
August 24, 2010
Publication date:
February 24, 2011
Applicant:
SAMSUNG ELECTRONICS CO., LTD.
Inventors:
YOON KONG, BYOUNG-KUK NA, SEON-HEE KIM, YOUNG-AN BAE
Abstract: The invention aims to provide a novel alkaline protease having peculiar properties such as high alkali activity, resistance to surfactants and calcium-dependent thermostability and exhibiting excellent performance in highly alkaline detergents, and a gene coding for the amino acid sequence thereof. There is provided an alkaline protease with such properties that an active pH range is from 5 to 13, an optimum pH is approximately 12.6, an optimum temperature is 70° C., no activity drop by heating is observed up to 65° C. at pH 10 and the optimum temperature and the thermostability are not affected by Ca2+ ions. Specifically, there is provided, for example, an alkaline protease having an amino acid sequence constituting a mature enzyme as represented by SEQ ID NO: 3 or an amino acid sequence resulting from deletion, substitution, situs inversus arrangement, addition or insertion of a part of amino acids thereof, or derived from Alkaliphillus transvaalensis.
Type:
Application
Filed:
November 16, 2005
Publication date:
February 24, 2011
Applicant:
Japan Agency for Marine-Earth Science and Tech.
Inventors:
Jie Lu, Zhijun Li, Si Hung Vo, Yuji Hatada, Ken Takai, Susumu Ito, Koki Horikoshi
Abstract: A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation.
Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
Abstract: The present invention provides an aqueous composition and method for extracting nucleic acid from a sample of bodily fluid, such as saliva, such that the nucleic acid within said sample remains stable for at least fourteen days at room temperature. The composition permits direct use of the extracted and stored DNA in an amplification reaction without further processing.
Type:
Application
Filed:
June 3, 2010
Publication date:
January 20, 2011
Applicant:
DNA GENOTEK INC.
Inventors:
Chaim H. BIRNBOIM, Adele JACKSON, Rafal IWASIOW, Joanne CHARTIER, Paul LEM
Abstract: The present invention is directed to the identification of a protease prodomain that is capable of binding a corresponding protease with high affinity. The protease prodomain of the present invention is fused to a second protein to form a protease prodomain fusion protein. The presence of a protease prodomain protein in a fusion protein allows for easy and selective purification of the second protein by incubation with the corresponding protease.
Abstract: The present invention relates to subtilase subtilases with an altered immunogenicity, particularly subtilases with a reduced allergenicity. Furthermore, the invention relates to expression of said subtilase variants and subtilases and to their use, such as in detergents and oral care products.
Abstract: The present invention relates to a novel protease, a polynucleotide encoding the protease, and a fibrinolytic agent comprising the same. The protease is obtained from a new gene source by using metagenomic library technology, and can replace the conventional fibrinolytic agent.
Type:
Grant
Filed:
November 8, 2006
Date of Patent:
January 11, 2011
Assignee:
Korea Ocean Research and Development Institute
Inventors:
Sang-Hyeon Lee, Dong-Geun Lee, Jeong-Ho Jeon, Nam-Young Kim, Jung-Hyun Lee, Sang-Jin Kim, Min-Kyung Jang
Abstract: A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.
Type:
Application
Filed:
May 8, 2007
Publication date:
January 6, 2011
Applicant:
INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL
Inventors:
Nabil G. Seidah, Jean Davignon, Geneviève Dubuc, Lise Bernier, Michel Tremblay
Abstract: It is an object of the present invention to provide a non-human gene-disrupted animal with a disrupted ADAM11 gene. According to the present invention, a non-human gene-disrupted animal, wherein either one of or both alleles of an ADAM11 gene are disrupted, is provided.
Type:
Application
Filed:
July 12, 2006
Publication date:
December 30, 2010
Applicant:
EISAI R&D MANAGEMENT CO., LTD
Inventors:
Koji Sagane, Eiki Takahashi, Kazuto Yamazaki, Turo Oki
Abstract: The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
Type:
Application
Filed:
August 6, 2010
Publication date:
December 30, 2010
Applicant:
NOVO NORDISK A/S
Inventors:
SHAWN DEFREES, ROBERT J. BAYER, CARYN BOWE, KRISHNASAMY PANNEERSELVAM
Abstract: The invention is related to processing enzyme comprising an N-terminally attached tag derived from highly basic proteins from thermophilic bacteria. The processing enzymes are useful for modifying proteins. They can be produced in high yields and can be effectively separated from the modified protein after use.
Abstract: The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent.
Type:
Application
Filed:
August 16, 2010
Publication date:
December 9, 2010
Applicant:
Novozymes A/S
Inventors:
Preben Nielsen, Poul Erik Pedersen, Helle Outtrup
Abstract: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
Type:
Grant
Filed:
June 23, 2009
Date of Patent:
December 7, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
Gabriel A. Mintier, Jian Chen, John N. Feder, Bowman Miao, Rex Arnold Parker
Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.
Abstract: The present application relates to two novel proteases (SEQ ID NO: 4 and 7) which are similar to one another, whose DNA was obtained from soil samples, and C-terminally deleted, likewise proteolytically active fragments thereof (SEQ ID NO: 5 and 8), all alkaline proteases similar at least to 90% to SEQ ID NO: 4 or to 87.5% to SEQ ID NO: 7, and those which can be summarized under a consensus sequence (SEQ ID NO: 9) derived from SEQ ID NO: 4 and 7. Furthermore, it relates to all nucleic acids which have a homology of at least 85% identity to the associated nucleic acids (SEQ ID NO: 3 and 6) or the fragments concerned. Furthermore, it defines technical possibilities of use for these proteases and especially describes their use in detergents and cleaners.
Type:
Application
Filed:
March 5, 2010
Publication date:
November 25, 2010
Inventors:
Susanne Wieland, Karl-Heinz Maurer, Beatrix Kottwitz, Frank Niehaus, Patrick Lorenz
Abstract: The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and methods of treatment.
Abstract: The present invention relates to methods for pretreating biological samples for extraction of nucleic acid therefrom. The present invention employs a combination of at least one protein denaturant with one or more of the following elements to form a reaction mixture for extraction of nucleic acid: (1) at least one aprotic solvent, (2) stepwise heating, and (3) sample dilution.
Type:
Application
Filed:
May 12, 2010
Publication date:
November 11, 2010
Applicant:
BECTON, DICKINSON AND COMPANY
Inventors:
Matthew P. Collis, Donald Copertino, Karen Eckert, Thomas Fort
Abstract: Provided are modified matrix metalloprotease (MMP) enzymes that exhibit temperature-dependent activity and uses thereof. The MMPs can be used, for example, to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.
Type:
Application
Filed:
March 5, 2010
Publication date:
November 11, 2010
Inventors:
Louis Bookbinder, Gregory I. Frost, Gilbert Keller, Gerhard Johann Frey, Hwai Wen Chang, Jay Milton Short
Abstract: Disclosed herein are diagnostic markers for lung cancer, isolated from serum glycoproteins. The disclosed diagnostic markers for lung cancer are specifically expressed only in the sera of lung cancer patients at high levels, and thus will be very useful for diagnosing lung cancer and estimating disease progression and treatment.
Type:
Application
Filed:
September 6, 2007
Publication date:
November 11, 2010
Inventors:
Je-Yeol Cho, Jae-Yong Park, Seung-Jin Lee
Abstract: The invention relates to a process for the recombinant production of a heterologous polypeptide of interest by cultivating a bacterial host cell transformed with an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide wherein (a) the amino-proximal fusion partner is an autoprotease Npro comprising the replacement(s) by glutamic acid of one or more cysteines at positions corresponding to the positions 112, 134, and 138 of the autoprotease Npro of classical swine fever virus and (b) the carboxyl-proximal fusion partner is an heterologous polypeptide of interest fused to the autoprotease Npro so that it is capable of being cleaved from the fusion polypeptide by autoprotease Npro autoproteolytic activity, said process comprising (i) cultivating the transformed host cell under conditions permitting the expression of the fusion polypeptide and the formation of corresponding cytoplasmic inclusion bodies, (ii) isolating the inclusion bodies from the host cell, (iii) solubilizing the isol
Type:
Grant
Filed:
April 25, 2006
Date of Patent:
November 9, 2010
Assignees:
Sandoz AG, Boehringer Ingelheim RCV GmbH & Co KG
Inventors:
Florian Werther, Clemens Achmüller, Philipp Wechner, Bernhard Auer, Silvio Podmirseg
Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
Type:
Grant
Filed:
February 9, 2010
Date of Patent:
November 2, 2010
Assignee:
Schering Corp.
Inventors:
Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey O. Strickland
Abstract: The present invention provides an aqueous composition comprising SDS, Cyclohexanediamine tetraacetate, Tris-HCl and proteinase K for the extraction of nucleic acid from a sample of bodily fluid, such a saliva, wherein the extracted nucleic acid is stable for at least fourteen days at room temperature The composition permits direct use of the extracted and stored DNA in an amplification reaction without further processing.
Type:
Application
Filed:
April 12, 2010
Publication date:
October 28, 2010
Applicant:
DNA GENOTEK INC.
Inventors:
Chaim H. BIRNBOIM, Adele Jackson, Rafal Iwasiow, Joanne Chartier, Paul Lem
Abstract: A method for producing solid proteinase K which is insoluble in water and has high purity, the method comprising the steps of adding to an aqueous solution of proteinase K ammonium sulfate in an amount of 0.1 to 0.2 M per 5 minutes up to a final amount of 1.5 to 2 M after 1 hour, thereby precipitating the proteinase K as a solid, and isolating the solid proteinase K.
Type:
Grant
Filed:
September 29, 2006
Date of Patent:
October 26, 2010
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Helmut Schoen, Guenter Guertler, Bernhard Rexer, Johann-Peter Thalhofer
Abstract: Methods of using monoclinic crystals of human beta-secretase (BACE) having unit cell dimensions of a, b, and c, wherein a is about 81±20 ? to about 101 ?, b is 103±20 ?, c is 100±20 ?, and ?=?=90°, and ? is 105°±10° for crystals of symmetry P21 and a=73.1, b=105.1, c=50.5 ? and ? is 94.8° for crystals of C2 symmetry in drug screening assays comprising selecting a potential modifier by adding the potential modifiers to an aqueous mixture of the crystal and detecting a measure of binding, such that the potential modifier that binds is selected as a potential drug.
Type:
Grant
Filed:
December 6, 2008
Date of Patent:
October 19, 2010
Assignee:
Elan Pharmaceuticals, Inc.
Inventors:
Timothy Benson, D. Danielle Woods, Donald Prince
Abstract: The present disclosure relates in general to methods for recombinantly producing soluble, active IgA proteases (e.g., IgA1 proteases) in host cells (e.g., bacterial cells), and methods for using IgA proteases (e.g., IgA1 proteases) produced by the methods to treat IgA deposition disorders (e.g., IgA nephropathy).
Abstract: A recombinant vector comprises simian adenovirus SAdV-31 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-31 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.
Type:
Application
Filed:
November 24, 2008
Publication date:
October 14, 2010
Applicant:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Soumitra Roy, James M. Wilson, Luc H. Vandenberghe
Abstract: The present invention relates to a method for the purification of alpha-1 proteinase inhibitor (a1PI) from protein fractions. More specifically, the invention relates to an improved method for the purification of alpha-1 proteinase inhibitor (a1PI), wherein the yield of a1PI can be increased by thawing the starting material and incubating it for several hours before subjecting it to a washing step.
Type:
Grant
Filed:
August 11, 2005
Date of Patent:
October 5, 2010
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Peter Matthiessen, Gerald Brachtl, Peter Turecek, Hans-Peter Schwarz
Abstract: This invention relates to the detection and analysis by mass spec of nascent proteins, and in particular truncated proteins, translated within cellular or cell-free translation systems. N-terminal and C-terminal epitopes introduced into these nascent proteins permit rapid and efficient isolation, as well as a mass difference.
Type:
Grant
Filed:
July 30, 2004
Date of Patent:
October 5, 2010
Assignee:
AmberGen, Inc.
Inventors:
Alex M. Garvin, Sadanand Gite, Vladislav B. Bergo, Kenneth J. Rothschild